drugset / Trial / NCT07051915
The Holistic Study
Phase 3
Not yet recruiting
220 enrolled
Ostfold Hospital Trust
Haukeland University Hospital · collabHelse Fonna · collabHelse Nord-Trøndelag HF · collabHelse Stavanger HF · collabNordlandssykehuset HF · collabOslo University Hospital · collabSorlandet Hospital HF · collabSt. Olavs Hospital · collabSykehuset i Vestfold HF · collabUniversity Hospital of North Norway · collabUniversity Hospital, Akershus · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a phase 3 study where eligible patients will be randomized 1:1 to one of two treatment strategies: receiving a thrombopoietin receptor agonist (Avatrombopag), or anti-CD20 (Rituximab).
Timeline
- Start
- 2025-09-15
- Primary completion
- 2028-01-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avatrombopag | Small molecule | 20 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 1000 mg | Intravenous |